AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26145565 — intervention group
Group type: EXPERIMENTAL
Intervention: High estradiol and progesterone levels
Number of subjects: 73
Study 26145565 — intervention group
Group type: COMPARATOR
Intervention: Low estradiol group
Number of subjects: 73
Study 23802989 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy in addition to the standard rehabilitation program
Number of subjects: 200
Study 23802989 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Number of subjects: 200
Study 20978244 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (Culturelle)
Number of subjects: 36
Study 20978244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inulin alone)
Number of subjects: 36
Study 18369657 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 14
Study 18369657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18369657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 14
Study 17117294 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate calcium intake (1000-1500 mg/d) from dairy foods
Number of subjects: 0
Study 12951630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily
Number of subjects: 8
Study 12951630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11078265 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 1095
Study 11078265 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 1095
Study 11078265 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients
Number of subjects: 1095
Study 11078265 — intervention group
Group type: COMPARATOR
Intervention: US patients
Number of subjects: 1095
Study 8831471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 PT and 1 OT per 50 beds (enhanced group)
Number of subjects: 115
Study 8831471 — intervention group
Group type: COMPARATOR
Intervention: 1 PT and 1 OT per 200 beds (control group)
Number of subjects: 115
Study 1430299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefprozil 250 mg
Number of subjects: 24
Study 1430299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefprozil 500 mg
Number of subjects: 24
Study 1430299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefprozil 1000 mg
Number of subjects: 24
Study 1430299 — intervention group
Group type: COMPARATOR
Intervention: Oral cefprozil 500 mg
Number of subjects: 24
Study 2864374 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (oxprenolol) treatment
Number of subjects: 6357
Study 2864374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6357
Study 31888728 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Tongbi decoction
Number of subjects: 100
Study 31888728 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 100
Study 28871506 — intervention group
Group type: EXPERIMENTAL
Intervention: Project RISE intervention
Number of subjects: 165
Study 27664491 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day resveratrol capsules
Number of subjects: 56
Study 27664491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24723209 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin-fixed paraffin-embedded (FFPE) tonsil tissue specimens
Number of subjects: 4095
Study 24723209 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogenised fresh-frozen tonsil tissue
Number of subjects: 4095
Study 24723209 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of HPV infection
Number of subjects: 4095
Study 22124524 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT intervention (3 sessions per week for 6 weeks, low-intensity cycling with brief sprints)
Number of subjects: 29
Study 22124524 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT intervention
Number of subjects: 29
Study 22124524 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained normal sedentary lifestyle)
Number of subjects: 29
Study 20555273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion
Number of subjects: 8
Study 20555273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride; NaCl)
Number of subjects: 8
Study 18084172 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (treadmill walking, thrice a week for 8 weeks)
Number of subjects: 60
Study 18084172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 60
Study 16282517 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg
Number of subjects: 144
Study 16282517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 20 mg
Number of subjects: 144
Study 16282517 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 144
Study 16282517 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 144
Study 11898803 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 degrees angled telescope
Number of subjects: 10
Study 11898803 — intervention group
Group type: COMPARATOR
Intervention: 0 degrees telescope
Number of subjects: 10
Study 11898803 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 and 45 degrees telescopes
Number of subjects: 10
Study 10536125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg once daily)
Number of subjects: 1559
Study 10536125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg twice daily)
Number of subjects: 1559
Study 10536125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1559
Study 10536125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (combined groups)
Number of subjects: 1559
Study 8808537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle taping
Number of subjects: 24
Study 8808537 — intervention group
Group type: COMPARATOR
Intervention: Untaped (control)
Number of subjects: 24
Study 8808537 — intervention group
Group type: COMPARATOR
Intervention: Athletic footwear (untaped)
Number of subjects: 24
Study 8808537 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic footwear (taped)
Number of subjects: 24
Study 2252170 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with propofol and alfentanil
Number of subjects: 40
Study 2252170 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anaesthesia with nitrous oxide and enflurane at 1.3 MAC
Number of subjects: 40
Study 7027059 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 0171 (VCR, PRED, MTX, cyclophosphamide +/‐ +/‐ 6‐MP)
Number of subjects: 38
Study 7027059 — intervention group
Group type: COMPARATOR
Intervention: Regimen 'A' (without 6‐MP in intensification)
Number of subjects: 38
Study 7027059 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 'B' (with 6‐MP in intensification)
Number of subjects: 38
Study 7027059 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 0276/A
Number of subjects: 38
Study 7027059 — intervention group
Group type: EXPERIMENTAL
Intervention: Best regimen
Number of subjects: 38
Study 7027059 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responders
Number of subjects: 38
Study 7027059 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapses
Number of subjects: 38
Study 31521525 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid insurance
Number of subjects: 96
Study 31521525 — intervention group
Group type: COMPARATOR
Intervention: Blue Cross Blue Shield (BCBS) private insurance
Number of subjects: 96
Study 31521525 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid insurance in expanded states
Number of subjects: 96
Study 31521525 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid insurance in unexpanded states
Number of subjects: 96
Study 30507375 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg
Number of subjects: 101
Study 30507375 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 101
Study 30507375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 26871245 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up for 3 months
Number of subjects: 88
Study 26871245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education and telephone follow-up)
Number of subjects: 88
Study 26871245 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up
Number of subjects: 88
Study 25483647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent CYD vaccine against serotypes 1 and 3 (CYD-1;3) on day 0 and CYD-2;4 on day 105 (± 15 days)
Number of subjects: 150
Study 25483647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent blend of CYD-1;3;4 and VERO cell derived, live attenuated vaccine against serotype 2 (VDV-2)
Number of subjects: 150
Study 25483647 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference CYD-TDV
Number of subjects: 150
Study 25483647 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis (JE) vaccine followed by CYD-TDV
Number of subjects: 150
Study 25483647 — intervention group
Group type: COMPARATOR
Intervention: Tetravalent CYD vaccine (CYD-TDV)
Number of subjects: 150
Study 22006544 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 82
Study 22006544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 19236546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combizym treatment (2 weeks, two tablets post-meal, t.i.d.)
Number of subjects: 151
Study 19236546 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (2 weeks, two tablets post-meal, t.i.d.)
Number of subjects: 151
Study 17999733 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific paste for complete dentures (Corega Brite)
Number of subjects: 45
Study 17999733 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral soap
Number of subjects: 45
Study 17999733 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 45
Study 15470286 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (irbesartan, olmesartan medoxomil, telmisartan, valsartan) in combination with hydrochlorothiazide (40 mg/25 mg)
Number of subjects: 0
Study 15470286 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers with hydrochlorothiazide
Number of subjects: 0
Study 15470286 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with either angiotensin II receptor blockers or hydrochlorothiazide
Number of subjects: 0
Study 11828263 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose dacarbazine (arm A)
Number of subjects: 219
Study 11828263 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dacarbazine (arm B)
Number of subjects: 219
Study 11828263 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive regimen without dacarbazine (arm C)
Number of subjects: 219
Study 11828263 — intervention group
Group type: COMPARATOR
Intervention: Non-aggressive regimen without dacarbazine (arm D)
Number of subjects: 219
Study 10078673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine-4 microg fentanyl
Number of subjects: 30
Study 10078673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine-2 microg fentanyl
Number of subjects: 30
Study 10078673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% ropivacaine-1 microg fentanyl
Number of subjects: 30
Study 7747374 — intervention group
Group type: EXPERIMENTAL
Intervention: UroLume endourethral prosthesis
Number of subjects: 175
Study 2105243 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG + GH (24 IU on alternate days, total dose 144 IU)
Number of subjects: 16
Study 2105243 — intervention group
Group type: COMPARATOR
Intervention: hMG + placebo
Number of subjects: 16
Study 2105243 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG + GH
Number of subjects: 16
Study 548209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin administration
Number of subjects: 8
Study 548209 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study 31708453 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured telephone interviews
Number of subjects: 12
Study 31708453 — intervention group
Group type: EXPERIMENTAL
Intervention: Research priorities identified by participants
Number of subjects: 12
Study 31182060 — intervention group
Group type: EXPERIMENTAL
Intervention: Running therapy (exercise planned two times a week for 6 months)
Number of subjects: 46
Study 31182060 — intervention group
Group type: EXPERIMENTAL
Intervention: Running therapy
Number of subjects: 46
Study 31182060 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 46
Study 28063226 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartcare with financial incentives
Number of subjects: 105
Study 28063226 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartcare
Number of subjects: 105
Study 28063226 — intervention group
Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 105
Study 25637146 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese massage combined with core stability exercises
Number of subjects: 92
Study 25637146 — intervention group
Group type: COMPARATOR
Intervention: Chinese massage alone
Number of subjects: 92
Study 23657159 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg
Number of subjects: 10
Study 23657159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21836137 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous control of tracheal cuff pressure using a pneumatic device
Number of subjects: 122
Study 21836137 — intervention group
Group type: COMPARATOR
Intervention: Routine care of tracheal cuff pressure
Number of subjects: 122
Study 18703258 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) multimedia on vital signs with animation and audio features, used in conjunction with traditional lecture or lecture-demonstration.
Number of subjects: 0
Study 18703258 — intervention group
Group type: COMPARATOR
Intervention: Control group using traditional lecture or lecture-demonstration without CAL.
Number of subjects: 0
Study 16774872 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal (CC) filter tipped cigarettes
Number of subjects: 39
Study 16774872 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate (CA) filter tipped cigarettes
Number of subjects: 39
Study 10830450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention children (dietary fat modification counseling)
Number of subjects: 200
Study 10830450 — intervention group
Group type: COMPARATOR
Intervention: Control children (no dietary fat modification counseling)
Number of subjects: 200
Study 8901078 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg controlled-release (CR) oxycodone tablet
Number of subjects: 22
Study 8901078 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg immediate-release (IR) oxycodone solution
Number of subjects: 22
Study 1670668 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) in cerebrospinal fluid
Number of subjects: 41
Study 1670668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for cerebrospinal fluid antibodies
Number of subjects: 41
Study 1670668 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 41
Study 1670668 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 pyogenic meningitis, 3 aseptic meningitis, 34 other neurological disorders)
Number of subjects: 41
Study 1670668 — intervention group
Group type: COMPARATOR
Intervention: Antibody ELISA in controls
Number of subjects: 41
Study 6666226 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ISDN (acute treatment)
Number of subjects: 12
Study 6666226 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 X 60 mg ISDN (4 weeks treatment)
Number of subjects: 12
Study 6666226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29401495 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiotherapy
Number of subjects: 203
Study 29401495 — intervention group
Group type: COMPARATOR
Intervention: Deferred radiotherapy (control)
Number of subjects: 203
Study 27345284 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 744 mg (delivering 400 mg isavuconazole)
Number of subjects: 64
Study 27345284 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate (oral administration)
Number of subjects: 64
Study 27345284 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate 372 mg (delivering 200 mg isavuconazole) with esomeprazole 40 mg/day
Number of subjects: 64
Study 24594863 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation (1,000 mg of elemental calcium + 400 IU of vitamin D3 daily)
Number of subjects: 600
Study 24594863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 22648731 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g per day of cis9,trans11 CLA‐enriched oil
Number of subjects: 40
Study 22648731 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (palm oil and soybean oil)
Number of subjects: 40
Study 20079786 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (97 mg) and caffeine (40 mg)
Number of subjects: 0
Study 20079786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17639029 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (single and multiple dosing)
Number of subjects: 34
Study 17639029 — intervention group
Group type: EXPERIMENTAL
Intervention: Model comparison
Number of subjects: 34
Study 17639029 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations of linezolid concentration-time profiles
Number of subjects: 34
Study 16343096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) administration after metformin treatment (group A)
Number of subjects: 28
Study 16343096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) administration after laparoscopic ovarian drilling (LOD) (group B)
Number of subjects: 28
Study 12410501 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-mediated closure device (SMC); n = 96
Number of subjects: 193
Study 12410501 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC); n = 97
Number of subjects: 193
Study 10051054 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network (NN) combined with genetic algorithm (GA) for predicting tacrolimus blood levels
Number of subjects: 32
Study 10051054 — intervention group
Group type: COMPARATOR
Intervention: Observed tacrolimus blood levels
Number of subjects: 32
Study 7796303 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition test without specific instructions on encoding
Number of subjects: 0
Study 7796303 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific encoding instructions
Number of subjects: 0
Study 7796303 — intervention group
Group type: COMPARATOR
Intervention: Test conditions without specific encoding instructions (Experiment 2B)
Number of subjects: 0
Study 31829793 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee cherry extract (CCE)
Number of subjects: 71
Study 31829793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31574228 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral perfusion-targeted resuscitation
Number of subjects: 0
Study 31574228 — intervention group
Group type: COMPARATOR
Intervention: Lactate-targeted resuscitation
Number of subjects: 0
Study 27304977 — intervention group
Group type: COMPARATOR
Intervention: No enema
Number of subjects: 333
Study 27304977 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride enema
Number of subjects: 333
Study 27304977 — intervention group
Group type: COMPARATOR
Intervention: Soap-suds enema (SSE)
Number of subjects: 333
Study 27304977 — intervention group
Group type: EXPERIMENTAL
Intervention: No bowel preparation
Number of subjects: 333
Study 27304977 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 333
Study 26152410 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidacloprid 10 % (w/w) / Flumethrin 4.5 % (w/w) collar (Seresto)
Number of subjects: 0
Study 26152410 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral afoxolaner chewable (NexGard) (dosage 3.1 - 6.2 mg/kg)
Number of subjects: 0
Study 26152410 — intervention group
Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 0
Study 22727976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5mg daily (n=27)
Number of subjects: 45
Study 22727976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 45
Study 20943711 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 46
Study 20943711 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 46
Study 20943711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Pharmacotherapy + Physiotherapy)
Number of subjects: 46
Study 19649309 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 to 300 mg/day)
Number of subjects: 15
Study 19649309 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (10 to 20 mg/day)
Number of subjects: 15
Study 17609874 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR-BT (18 Gy, 9 Gy on days 1 + 8) plus 50.4 Gy of EBRT in group B (applicators in both prostate and SV)
Number of subjects: 41
Study 17609874 — intervention group
Group type: COMPARATOR
Intervention: HDR-BT (18 Gy, 9 Gy on days 1 + 8) plus 50.4 Gy of EBRT in group A (applicators in prostate only)
Number of subjects: 41
Study 17609874 — intervention group
Group type: COMPARATOR
Intervention: Group A (prostate only)
Number of subjects: 41
Study 17609874 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (prostate and SV)
Number of subjects: 41
Study 17609874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 15200753 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 271
Study 15200753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen 10/650 mg (single dose)
Number of subjects: 271